A pilot study of peripheral blood BDCA-1 (CD1c) positive dendritic cells pulsed with NY-ESO-1 ISCOMATRIX™ adjuvant

• Published in: Immunotherapy Vol. 9; no. 3; pp. 249 - 259
• Main Authors: Davis, Ian D, Quirk, Juliet, Morris, Leone, Seddon, Lauren, Tai, Tsin Yee, Whitty, Genevieve, Cavicchiolo, Tina, Ebert, Lisa, Jackson, Heather, Browning, Judy, MacGregor, Duncan, Wittke, Frederick, Winkels, Gregor, Alex, Regina, Miloradovic, Lena, Maraskovsky, Eugene, Chen, Weisan, Cebon, Jonathan
• Format: Journal Article
• Language: English
• Published: England Future Medicine Ltd 01.03.2017
• Subjects: Aged; Antigen Presentation; Antigens; Antigens, CD1 - metabolism; Antigens, Neoplasm - metabolism; Blood Cells - physiology; Blood Cells - transplantation; Cancer therapies; Cancer Vaccines - immunology; Carcinoma, Basal Cell - immunology; Carcinoma, Basal Cell - pathology; Carcinoma, Basal Cell - therapy; CD1c antigen; Cells, Cultured; Cholesterol - metabolism; clinical trial; Clinical trials; Clonal selection; Dendritic cells; Dendritic Cells - physiology; Dendritic Cells - transplantation; Drug Combinations; Female; Follow-Up Studies; Glycoproteins - metabolism; Humans; Immunity, Humoral; Immunogenicity; Immunomodulation; Immunotherapy; Immunotherapy - methods; ISCOMATRIX™ adjuvant; Lymphocyte Activation; Lymphocytes; Lymphocytes B; Male; Melanoma; Membrane Proteins - metabolism; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; NY-ESO-1; Patients; Peptides; Peripheral blood; Phospholipids - metabolism; Pilot Projects; Positive selection; Proteins; Remission; Saponins - metabolism; Skin cancer; Skin Neoplasms - immunology; Skin Neoplasms - pathology; Skin Neoplasms - therapy; T-Lymphocytes - immunology; Toxicity; Treatment Outcome; Tumors; Vaccines; United States > US; NY-ESO-1; clinical trial; ISCOMATRIX™ adjuvant; dendritic cells; antigens
• ISSN: 1750-743X; 1750-7448
• DOI: 10.2217/imt-2016-0132

Pilot clinical trial of NY-ESO-1 (ESO) protein in ISCOMATRIX™ adjuvant pulsed onto peripheral blood dendritic cells (PBDC), to ascertain feasibility, evaluate toxicity and assess induction of ESO-specific immune responses. Eligible participants had resected cancers expressing ESO or LAGE-1 and were at high risk of relapse. PBDC were produced using CliniMACS plus, with initial depletion of CD1c B cells followed by positive selection of CD1c PBDC. Patients received three intradermal vaccinations of ESO/IMX-pulsed PBDC at 4-week intervals. The process was feasible and safe. No vaccine-induced immune responses were detected. Assays of immunomodulatory cells did not correlate with outcomes. One patient had a long lasting complete remission. This method was feasible and safe but was minimally immunogenic.